When it comes to heart health, the prevalence of a condition shouldn’t be much of a comfort for those dealing with symptoms. While it’s always good to ...

The most serious complications of untreated AFib include the following: Rapid ventricular rate (RVR) is a complication of ...

Etripamil for patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025. Milestone plans to initiate a ...

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

Etripamil for patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025. Milestone plans to initiate a ...

However, with a Phase 3 trial for etripamil expected to begin enrollments in 2025 for patients with atrial fibrillation with ...

Commercial capabilities build out in process, with proposed launch in PSVT targeted for mid-2025 - Plans to initiate Phase 3 Study in AFib-RVR in H1 2025 MONTREAL and CHARLOTTE, N.C., Jan.

Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025. Milestone plans to initiate a trial of etripamil nasal spray in patients with AFib-RVR in the at-home setting.

Milestone Pharmaceuticals Inc. announced that the PDUFA date for its nasal spray CARDAMYST™ (etripamil) for treating Paroxysmal Supraventricular Tachycardia (PSVT) has been set for March 27, 2025.